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Background: Great saphenous vein (GSV) reflux is the most frequent form of venous insufficiency in symptomatic patients
and is commonly responsible for varicose veins of the lower extremity. This non-randomized prospective controlled study
was designed to test the hypothesis that 1) endovenous laser treatment is more effective than foam sclerotherapy in the
closure of the refluxing GSV (as measured by degree of great saphenous vein reflux and venous clinical severity score
changes) and 2) to record the associated complications of echo-guided endovenous chemical ablation with foam and
endovenous laser therapy for the treatment of great saphenous vein reflux and to further identify risk factors associated
with treatment failure.
Methods: Between January 1, 2006 and June 25, 2006, patients seeking treatment of varicose veins at a private practice of
vascular medicine were assessed for the study. Inclusion criteria were: 1) presence of great saphenous vein reflux and
2) C2-6, Epr, A s, according to the CEAP classification. The selected patients consented into the study and were allowed
to choose between foam (53 patients) or laser (45 patients) treatment. Duplex examinations were performed prior to
treatment and at seven and 14 days, four weeks, six months, and one year after treatment. Venous clinical severity score
was assessed pre-treatment and at one year post-procedure.
Results: The cohorts showed no statistically significant differences in age, sex, clinical and anatomical presentation, great
saphenous vein diameter, and venous clinical severity score before the treatments. After one year follow up, occlusion of
the great saphenous vein was confirmed in 93.4% (42/45) of limbs studied in the laser group and 77.4% (41/53) of limbs
in the foam group (P < .0465). Venous clinical severity score significantly improved in both groups (P < .0001).
Procedure associated pain was higher in the laser group (P < .0082). Induration, phlebitis, and ecchymosis were the most
common complications. Logistical regression and subgroups analysis shown that a larger great saphenous vein diameter
measured before treatment was associated with treatment failure in the foam (odds ratio 1.68, 95% CI 1.24-2.27, P <
.0008) and in the laser group (odds ratio 1.91, 95% CI 1.02-3.59, P < .0428). A 90% treatment success is predicted for
veins <6.5 mm in the foam group versus veins <12 mm in the laser group.
Conclusions: Overall, endovenous laser ablation achieved higher occlusion rates than echo-guided chemical ablation with
foam after one year follow-up. Matching the patient to the technique based on great saphenous vein diameter measured
before treatment may assist in boosting the treatment success rate to >90%. A larger patient cohort followed and
compared over a longer period of time would be required to confirm these findings. ( J Vasc Surg 2008;48:940-6.)Lower extremity venous insufficiency is a very com-
mon medical condition that affects approximately 25%
of women and 15% of men in the western countries1
and poses a big burden on an individual’s quality of
life as well on the resources and budgets of many coun-
tries’ health systems.2,3 In particular, great saphenous
vein (GSV) reflux is the most frequent form of venous
insufficiency and is commonly responsible for varicose
veins of the lower extremity and ulterior leg ulcer devel-
opment.2
The treatment of varicose veins has changed from sur-
gery to minimally invasive techniques. These include radio-
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940frequency closure of the saphenous vein, endovenous laser
obliteration of the saphenous vein, and the use of echo-
guided endovenous chemical ablation with foam, also
know as foam sclerotherapy.2 Besides the satisfactory es-
thetic and functional results obtained with these treatments
and their low rate of complications, most of them are
performed in outpatient facilities, under local anesthesia,
and with almost no “down time.”
Foam sclerotherapy and laser ablation are reported to
succeed in the complete closure of the treated vein in
around 85% and 95% of the cases, respectively, at two years
follow up, and the rate of severe adverse events is under 1%.
Thus, they are the favored methods of treatment in several
clinical centers.4-6 However, the efficacy and complications
of these techniques have not been established in prospec-
tive side-by-side studies.7
We perform both procedures routinely at the Clínica de
Várices Doctor González Folch, and in this article we
evaluate the treatment success rate, complications, and
indications of GSV reflux treatment with either laser abla-
tion or echo-guided chemical ablation with foam in a
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hemodynamic follow-up cohort study.
METHODS
Patients and study description
In the period between January 1, 2006 and June 25,
2006, patients seeking varicose vein treatment were inter-
viewed and assessed for the study inclusion/exclusion cri-
teria by a physician using a standard interview and clinical
examination protocol. Once patients were found to meet
the study criteria, treatment options were explained using a
previously defined script. Both treatments were explained
as being essentially equivalent and patients were told both
treatments were considered among the best options for
treating varicose vein disease today. Ninety-eight patients
with primary isolated GSV incompetence and C2-6, Ep,
A s, presentation were educated about treatment options
and allowed to elect into one of two treatment groups:
Group 1 was treated with endovenous laser ablation and
Group 2 with echo-guided chemical ablation with foam.
Only one limb per patient was included and treated during
this period of time. A highly experienced surgeon per-
formed the procedures; the physician has performed over
800 endovenous laser therapies and over 2000 foam scle-
rotherapy therapies over a period of time exceeding five
years. This physician was blinded to the initial clinical
information of the patients and just followed the treatment
protocol as indicated.
Limbs were categorized according to the CEAP classifi-
cation (as stated by the North American Chapter of the
Society for Vascular Surgery and the International Society8).
Patients with primary incompetence of the GSV and
saphenofemoral junction insufficiency with a reflux time
0.5 seconds measured over a distance of at least 20 cm in
the upper leg were included.9 Exclusion criteria were preg-
nancy, active thrombophlebitis, clotting disturbances,
known thrombophylia or coagulation disorders, a history
of deep vein thrombosis, and malignancies in the patient’s
medical history.
The clinical and ultrasound follow-ups were done by a
physician blinded to the treatment options; the physician
followed aprotocol to conduct the examination.Therewas no
room for the patient to comment on his/her treatment and
patients were scheduled for the follow up visit in such a way
they could not get to know each other. No patients were lost
or excluded from the study during the study time frame.
Ethics committee approval and informed consent were
obtained. The study protocol conformed to the guidelines
of the 1975 Declaration of Helsinki.
Color duplex scanning
Pretreatment examination was performed using a color
duplex scanner (Medison Pico, Universal Ultrasound Sys-
tems Inc, Bedford, NY) with a 6- to 12-MHz transducer, to
detect venous reflux in the GSV and other venous pathol-
ogy such as deep venous insufficiency, obstruction, and
venous malformations. Duplex examination was performedat one and two weeks, one and six months and at one year
after treatment to determine reflux (when still present),
flow, venous occlusion or opening, compressibility, and
vein diameter 2 cm. below the saphenous femoral junction
(SFJ). All patients were thoroughly screened for deep ve-
nous thrombosis. Physical examination was performed to
determine outcomes and side effects, such as induration,
echimosys, phlebitis, and others. Venous clinical severity
score (VCSS)10 was assessed pre-treatment and at one year
post-procedure.
Endovenous laser ablation (ELA)
The procedure was carried out under local anesthesia in
an outpatient treatment facility. The GSV was identified by
duplex imaging in the standing position and marked from
groin following the path of reflux. While the patient was
lying down, the treatment leg was externally rotated and
flexed to 40° at the knee. The GSV at the point of the most
distal reflux was punctured with a 21-G needle under
ultrasonographic control and a guidewire passed up the
GSV. A 5-Fr introducer sheath was then passed over the
guidewire until the tip reached approximately 1 cm below
the SFJ. This position was confirmed by ultrasonography.
Tumescent local anaesthesia (10 ml. per cm. of GSV
length, 0.2% lidocaine) was infiltrated under ultrasono-
graphic control into the perivenous space. A 600 m laser
filament was passed through the sheath until the tip was
positioned 1 cm below the SFJ. Once in place, the laser
sheath was withdrawn, exposing 2 cm of the laser fiber.
Protective laser goggles weremandatory for staff and patients.
Laser energy was delivered by a 980-nm diode laser (ELVeS;
Biolitec, Jena, Germany) set at a power of 15 W. Slow fiber
withdrawal at a rate of 1-2 mm per second was employed in
continuous mode, delivering 70 to 90 joules/cm.
Echo-guided chemical ablation with foam (ECHA)
The procedure was carried out in an outpatient treat-
ment facility. The GSV was identified by duplex imaging in
the standing position and marked from groin following the
path of reflux. Sclerosing foams were prepared using the
technique described by Tessari, applying a sclerosant to air
ratio of 1:4.11,12 The treatment with echo-guided foam
sclerotherapy consisted of a single injection of 3% foam
(Polidocanol, Aet; Kreussler Pharma, Wiesbaden, Ger-
many), with the patient in supine position. The technique
involved ultrasound localization of the GSV, access using a
18 G venflon and slow injection of the foamed sclerosing
agent. This venflonwas placed in the insufficient GSV at the
point of the most distal reflux. The volume of foam to be
injected was calculated using a ratio of 1 ml per millimeter
of diameter of the GSV. The surgeon observing the filling
of the GSV decided the final volume. Injection was fol-
lowed by immediate compression of the SFJ with the
ultrasound probe during two minutes.
After endovenous laser and foam sclerotherapy a full-
length compression stocking (class II support hosiery;
GloriaMed, Menaggio, Italy) was applied 10 minutes post-
procedure with the patient lying down. Stockings were
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and for seven additional days where usage during the day
only was required. Patients were advised to walk immedi-
ately post procedure for 30 minutes and then discharged
home with written instructions to walk daily for 30 minutes
and to take simple, non-prescription analgesics for post-
procedural pain, if required.
Follow-up and assessment of outcome measures
At baseline and during follow-up at one month and at
one year after inclusion, a history was taken detailing clin-
ical and venous clinical severity score components. The
primary outcomemeasure was presence of reflux, measured
with duplex imaging. Success of treatment was defined as
complete occlusion of the treated vein. Secondary outcome
measures were pain associated with the procedure (analog
scale, 1 to 10), VCSS, deep vein thrombosis (DVT), phle-
bitis, ecchymosis, and paraesthesia.
Statistical analysis
A power analysis, using G*Power3 software13 was per-
formed to estimate the chances to test the hypothesis of a
20% difference in success rate between the two groups. We
chose to use 20% as the primary outcome effect size for two
main reasons; first, it is a clinically significant improvement
that would lead us to switch to a different treatment option
(about one in every five patients will get an extra benefit
from the new treatment) and, second, comparative analysis
across many trials looking at foam sclerotherapy and endo-
laser suggests a difference in efficacy of at most 20%. For a
power of 80% with a significant level targeted at 0.05 and
using a Fisher’s exact test, a group sample sizes of 45 in group
one and 45 in group two are necessary to test the hypothesis
that endovenous laser treatment performs better than foam
sclerotherapy in the closure of the refluxing GSV.
Comparison between the two groups was performed
with the Fisher’s exact test or 2 test for categorical vari-
ables and the Wilcoxon tests for continuous variables and
differences between pre- and post-procedure outcomes.
Statistical analyses were performed using GraphPad Prism
version 4.03 (GraphPad Software, San Diego, Cal) statisti-
cal package. Logistic regression analysis (on the web
http://statpages.org/logistic.html by John C. Pezzullo
and Kevin M. Sullivan) was used to assess the correlation
between outcome and continuous variables. P  .05 was
considered statistically significant.
RESULTS
Cohorts description
Ninety-eight patients were treated and represent the sub-
jects of this study. Eighty patients were women (81.6%) and
18 were men (18.4%), with a mean age of 52.5 11.9 years
(range, 26 to 78 years). Sixty-three patients had symptomatic
varicose veins, with or without edema (C2-C3), and thirty-
five had a history of skin changes with or without venous
ulcers (C4-C6). Etiology was primary superficial valvular in-
competence in all patients. Pre-procedure deep venous refluxand/or perforator reflux was detected in 15 patients (15.3%);
the detected deep venous reflux was negligible. Great saphe-
nous vein (GSV) diameter mean was 7.9  3.1 mm (range,
3 to 16 mm). Most patients presented with a low VCSS with
a median of 3 and an interquartile range of 3-5 (IQR). The
cohorts showed no statistically significant differences in age,
sex, clinical and anatomical presentation, GSV diameter, and
VCSS before the treatments, as depicted in Table I.
Primary and secondary outcomes
Early postoperative duplex ultrasound scans were per-
formed in all patients seven days after the procedure. These
studies revealed incomplete closure (opened, flux, and reflux)
in four limbs (7.6%) in the foam group and none (0%) in the
laser group. At the six month follow up visit, duplex ultra-
sound scans were performed in all patients. The analysis
showedpartialGSV recanalization in twopatients (cumulative
11.3% failure) in the foam group and one (2.2%) in the laser
group. The cumulative success rates at one year were 93.4%
Table I. Demographic and clinical data for 98 patients
to be treated with great saphenous vein endovenous laser
ablation or endovenous chemical ablation with foam
ELT ECHA P value
Number of patients 45 53
Male:female (n) 7:38 11:42 .6048
Age (years, mean  S.D.) 51.1  11.9 53.7  12.0 .3063
Clinical presentation (n, %) 1
C2 15 (33.3) 16 (30.2)
C3 16 (35.6) 16 (30.2)
C4 9 (20.0) 10 (18.9)
C5 3 (6.7) 6 (11.3)
C6 2 (4.4) 5 (9.4)
Anatomical classification
(n, %)
Superficial 45 (100.0) 53 (100.0)
Deep 3 (6.7) 4 (7.5) 1
Perforator 4 (8.9) 4 (7.5) 1
Diameter GSV (mm,
mean  S.D.) 8.2  3.2 7.6  3.0 .4288
VCSS (median, IQR) 3, 3-5 3, 3-5 .8112
ECHA, endovenous chemical ablation; ELA, endovenous laser ablation;
GSV, great saphenous vein; IQR, interquartile range; VCSS, venous clinical
severity score.
Table II. Primary outcomes after endovenous laser
ablation or endovenous chemical ablation with foam of
the GSV
Outcomes ELT ECHA P value
Number of patients 45 53
Overall results (n, %)
Occlusion 42 (93.4) 41 (77.4) .0465
Flux 3 (6.7) 12 (22.6) .0465
Reflux 1 (2.2) 8 (15.1) .0360
Open 1 (2.2) 8 (15.1) .0360
ECHA, endovenous chemical ablation; ELA, endovenous laser ablation;
GSV, great saphenous vein.(95% CI 81.5 to 98.4%) for the ELA group and 77.4% (95%
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in Table II. All the patients with GSV recanalization were
further treated with foam with a larger volume, but were
excluded from further analysis of this trial.
The successfully treated patient group was further eval-
uated in terms of VCSS and GSV diameter at the one-year
follow up. As shown in Fig 1, A, patients’ VCSS signifi-
cantly improve with treatment, either laser (VCSS before 3
IQR 3-5 to VCSS after 3 IQR 3-2, P  .0001) or foam
GSV ablation (from VCSS before 3 IQR 3-5 to VCSS after
2 IQR 3-2, P .0001). This improvement is also observed
when patients are subdivided into clinical presentation
groups (C2-C3 and C4-C5-C6 groups, P  .005, not
shown). GSV diameter was significantly reduced (Fig 1, B)
with both foam (6.9  2.3 to 3.4  1.1 mm, P  .0001)
and laser (8.0  3.0 to 3.9  1.3 mm, P  .0001)
treatments.
Variables affecting primary success rate
Patients were classified into arbitrary subgroups ac-
cording to their clinical presentation (C2-3 vs. C4-5-6) and
Fig 1. Box and whiskers plots to show, in A, changes in VCSS
after treatment with endovenous chemical ablation with foam or
laser endovenous GSV ablation and in B, changes in GSV vein
diameter after treatment with foam or laser endovenous GSV
ablation.GSV vein diameter (8, 8-12, and 12 mm) before treat-ment. As illustrated in Table III,the cumulative rate of
treatment failure at one year was not significantly different
in the clinical presentation subgroups; either treated with
foam (P  .5073) or laser (P  1, Table III). These
subgroups had comparable patient age and GSV diameter.
GSV vein diameter subgroups analysis shows an in-
crease in the failure rate from 7% in the8mm subgroup to
67% in the 12 mm subgroup treated with foam (P 
.0011). All the patients who experienced laser treatment
failure belong to the 12 mm subgroup (P  .0070). In
fact, successfully treated patients had an average GSV diam-
eter before treatment smaller than the failed treatment
patient groups, either in the foam (6.7 2.3 versus 10.8
3.1 mm, P  .0002) or laser (7.8  2.9 versus 13.3  2.3
mm, P  .0216) groups.
Logistic regression analysis shows that, indeed, results
were worse for greater diameter GSVs compared with
smaller diameter GSVs in both the foam (OR 1.68, 95% CI
1.24-2.27, P  .0008) and the laser (OR 1.91, 95% CI
1.02-3.59, P  .0428) treatment groups. A 90% success
rate (logistic regression model calculated probability) is
predicted for veins 6.5 mm in the foam group and veins
12 mm in the laser group. Other variables studied (clin-
ical presentation, age, and VCSS) showed no influence on
outcome (Table IV).
Postoperative complications and side effects
Deep vein thrombosis (DVT) was detected by routine
early postoperative scan after two foam ablation proce-
dures. There was one femoral vein occlusive vein thrombo-
sis and one partially occlusive gasctrocnemius vein throm-
bosis which represented 3.8% of the 53 patients (Table V).
All were asymptomatic and resolved within a short period
of treatment with subcutaneous low molecular weight hep-
arin therapy follow by oral anticoagulants. No DVT was
observed in the laser ablation treatment group. No clinical
episodes of pulmonary embolism or other cardiovascular
complications were observed. Phlebitis after treatment was
present 22.2% in the laser group versus 41.5% in the foam
group (P .0529). The incidence of ecchymosis (64.4% in
the laser group vs. 47.2% in the foam group, P  .1051)
and paraesthesia (4.4% in the laser group vs. 1.9% in the
foam group, P  .5923; Table V) was not statistically
different in the treatment groups. Induration (68.9% vs.
39.6% in the foam group, P  .0047) and pain associated
with the procedure (4.9  1.5 vs. 4.0  1.5 in the foam
group, P  .0082) were significantly higher in the laser
treatment.
DISCUSSION
Endovascular techniques of saphenous vein ablation
are minimally invasive alternatives to high ligation and
surgical stripping of the incompetent saphenous vein. This
non-randomized prospective study compared the early suc-
cess and complications of two endovenous procedures of
GSV ablation performed at a single institution in consecu-
tive patients.
V, gre
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ELA is consistent with other studies. Min et al14 reported a
failure rate of less than 7% at two year follow-up. Proebstle
et al15 reported recanalization in fewer than 10% of treated
GSVs at 12 month follow-up after ELA. A recent systemic
review of ELA has described 13 case series with encourag-
ing early and mid-term results.16
On the other hand, the proportion of occluded veins at
12months after foam sclerotherapy in our study population
appears to correspond with data reported by other authors
after two to three years of follow-up.17,18 Cabrera reported
an occlusion rate of 81% in the treatment of 500 GSVs
Table III. Variables affecting primary outcome after endo
foam of the GSV: subgroups analysis
Subgroups analysis
ECHA
n, % F
Clinical groups
C2-C3 32 (68.8)
C4-C5-C6 21 (31.2)
P value
GSV diameter groups
8 mm 28 (52.8)
8-12 mm 16 (30.1)
12 mm 9 (17.0)
P value
ECHA, endovenous chemical ablation; ELA, endovenous laser ablation; GS
Table IV. Variables affecting primary outcome after endo
foam of the GSV: logistic regression analysis
Logistic regression analysis
ECHA
O.R. 95% CI
Variable
Clinical groups C1-6 0.89 0.39-2.20
VCSS 0.97 0.44-2.15
Age 0.99 0.91-1.08
GSV diameter 1.68 1.24-2.27
CI, confidence interval; ECHA, endovenous chemical ablation; ELA, endo
odds ratio; VCSS, venous clinical severity score.
Table V. Complications and side effects after GSV
endovenous laser or chemical ablation with foam
Complications
(side effects)
ELA
(n  45)
ECHA
(n  53) P value
Pain (mean  SD) 4.9  1.5 4.0  1.5 .0082
Induration (n, %) 31 (68.9) 21 (39.6) .0047
Phlebitis (n, %) 10 (22.2) 22 (41.5) .0529
Ecchymosis (n, %) 29 (64.4) 25 (47.2) .1051
Paraesthesia (n, %) 2 (4.4) 1 (1.9) .5923
DVT (n, %) 0 (0.0) 2 (3.8) .4982
DVT, deep vein thrombosis; ECHA, endovenous chemical ablation; ELA,
endovenous laser ablation; GSV, great saphenous vein; Pain, treatment
associated pain.with a follow-up period of three years19 and Demagnyreported a recanalization of 11% after six months in 300
foam-treated GSVs.20 A recently published systematic re-
view of foam sclerotherapy places its efficacy around 85%.5
However, the limitation of the studies described is that
most of them did not provide comparative data with which
to evaluate the effectiveness of endovenous ablation against
other methods of treatment.
Surgical treatment is still considered the ‘gold standard’
for varicose veins in many centers. Nevertheless, the quali-
ties of conventional surgery have to be judged against the
newer minimally invasive techniques. Surgical ligation of
the SFJ, with or without GSV stripping, has been associated
with high recurrence rates, ranging from 18% to 62% at 10
years.21-23
Radiofrequency ablation is another relatively new tech-
nique for GSV obliteration, which has been used with
respectable success,24,25 but some studies reported a high
incidence of deep vein thrombosis (16%), paraesthesia
(10%), and skin burns (3.3%) with this technique.26
Regarding complications and adverse events, in this
study with endovenous ablation, induration, phlebitis, and
ecchymosis were the most frequent problems, but paraes-
thesia and DVT were rare. Surgery is associated with a risk
of saphenous nerve injury up to 40% with full-length GSV
stripping.27 Moreover, surgical treatment poses a risk of
scarring, haematoma formation, and wound infection. It is
worth mentioning that studies of foam sclerotherapy have
us laser ablation and endovenous chemical ablation with
ELA
e (n, %) n, % Failure (n, %)
9.3) 31 (68.9) 2 (6.5)
2.9) 14 (31.1) 1 (7.1)
073 1
.6) 21 (46.7) 0 (0.0)
1.2) 13 (28.9) 0 (0.0)
6.7) 11 (24.4) 3 (33.4)
011 .0070
at saphenous vein.
us laser ablation and endovenous chemical ablation with
ELA
P value O.R. 95% CI P value
.7890 2.87 0.33-24.77 .3373
.9463 0.31 0.03-3.12 .3226
.8519 0.94 0.79-1.09 .4091
.0008 1.91 1.02-3.59 .0428
s laser ablation; GSV, great saphenous vein; IQR, interquartile range; OR,veno
ailur
6 (1
6 (4
.5
1 (3
5 (3
6 (6
.0veno
venoureported a pulmonary embolism rate that ranged between
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without pulmonary embolism.28 DVT in ELA also has
been reported, with rates from 0% to 7.7%, and in agree-
ment with this study, induration, phlebitis, and ecchymosis
are the most frequent complications.4
Concerning this work, while it is a non-randomized
controlled study, major variables such as age, sex, CEAP,
GSV diameter, and VCSS before treatment were not statis-
tically different in the two treatment groups (Table I). With
respect to the primary outcome, ELA has an advantage over
foam sclerotherapy in terms of GSV closure rate at the one
year follow-up (93.4% vs. 77.4%, Table II) with a similar
profile of minor complications (Table V). Uncomplicated
DVT occurred in two patients treated with foam sclerother-
apy and in none of the patients treated with ELA. While no
significant differences were found in terms of complications
(with the exception of pain and induration), we must point
out that with a larger sample group some of the secondary
outcomes may turn out to be statistically significant.
In both treatment groups, the patients that achieved
GSV closure also showed a significant reduction in GSV
vein diameter (Fig 1, B). Clinical outcome, measured as
a change in the VCSS, also showed a significant improve-
ment in the severity score in both treatment groups
(Fig 1, A).
Failed cases were treated with one or more sessions of
foam sclerotherapy with a larger volume using the same
foam concentration (3%) until a successful outcome (de-
fined as GSV closure, no reflux, compression, or flow) was
achieved. The surgeon observing the filling of the GSV
decided the final volume; sometimes more than one session
was necessary. In the end, all the patients were successfully
treated, but because each one required a customized treat-
ment involving variable number of treatment sessions, scle-
rosant volume, and sites of injection, further analysis of this
sub-group was not possible.
To further gain understanding of covariates affecting
the primary outcome, a post hoc subgroup analysis and a
logistical regression analysis was performed. Both analyses
indicated that GSV diameter is a major factor in treatment
success rate. But most interestingly, the analyses also indi-
cated that ELAwill succeed with a wider range of GSV sizes
(larger diameter) than foam sclerotherapy. A conservative
extrapolation from the logistical regression analysis data
indicates that a 90% treatment success is predicted for veins
with a diameter 6.5 mm in the foam group versus veins
12 mm in the laser group. This data agree with a recently
published study where a Cox regression analysis of covari-
ates affecting echo-guided sclerotherapy indicated that a
vein diameter over 6 mm is associated with treatment
failure, and confirm our results that showed that age,
gender, and CEAP are not predictive of foam sclerotherapy
treatment outcomes (Tables III and IV).29
Considering that the overall total number of failures is
low in our study, an alternative explanation of the variables
with negative results over the outcome could be explained
because of a lack of power of the statistical analysis.CONCLUSION
In conclusion, ELA gave better results than ECHA
with foam in the treatment of GSV reflux at one year.
Minor complications were similar in both techniques. GSV
diameter before treatment should be considered when
choosing the therapeutic approach.
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